InsidersTradesSigma
申报总数
公司
▲ 买入（4 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
4
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Explore the full record of transactions filed by Alice Roudot-Ketelers, Chief Operating Officer. Director active across 1 company, notably INVENTIVA. Aggregated, 4 disclosures have been published. Split: 4 buys · 0 sell. Activity tracked since 8 December 2023. The latest transaction was disclosed on 7 January 2026 (ACQUISITION ACTIONS GRATUITES). Regulator: AMF. The full history is accessible without signup.
Companies and markets linked to Alice Roudot-Ketelers
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报4 总计
25,000 股0ActionHors plateforme de négociationISIN FR00132330122026DD1088249
标准退出：2026年4月7日 (T+90)
30,000 股0ActionHors plateforme de négociationISIN FR00132330122024DD1012792
标准退出：2025年3月26日 (T+90)
21,500 股0ActionHors plateforme de négociationISIN FR00132330122024DD959502
标准退出：2024年7月4日 (T+90)
15,000 股0ActionHors plateforme de négociationISIN FR00132330122023DD941947
标准退出：2024年3月7日 (T+90)
4 条申报中的 4 条
About Alice Roudot-Ketelers
Alice Roudot-Ketelers serves as Chief Operating Officer at Inventiva, following earlier responsibilities as Vice President Pharmaceutical & Clinical Development. Her career is rooted in the biopharmaceutical industry and spans more than 20 years of experience in clinical and pharmaceutical development. This background is especially relevant in an innovation-driven company such as Inventiva, where operational discipline and scientific execution are critical to advancing late-stage drug development programs. At Inventiva, she has been responsible for leading and overseeing the company’s global clinical and pharmaceutical development activities, including work tied to lanifibranor and the pivotal Phase III NATiV3 trial in NASH. Prior to joining Inventiva in 2021, Alice Roudot-Ketelers served as Vice President Clinical Development at Genfit from June 2014 to July 2021. There, she was in charge of all drug development programs and oversaw cross-functional teams spanning Chemistry, Manufacturing and Controls (CMC), non-clinical development, and clinical development through Phase III. That role gave her deep experience in managing complex development portfolios, aligning multidisciplinary teams, and executing programs within the regulatory and operational constraints of a listed biotech environment. Her move to Inventiva, announced in September 2021, came at a strategic moment as the company accelerated development of its pipeline and strengthened its operational capabilities in France and internationally. Her appointment as COO in February 2023 confirmed her central role in shaping and delivering the company’s development priorities. With academic training in pharmacy, including a Doctor of Pharmacy degree from the University of Lille and a master’s degree in pharmacy from the University of Lyon, she combines scientific expertise, clinical development know-how, and strong operational leadership. This makes her a key executive in the management of complex clinical programs within a high-growth publicly listed biopharmaceutical company.
